Airsculpt Technologies (AIRS) AI Stock Analysis

• Market Cap: $310.82M
• Dividend Yield: N/A
• Average Volume (3M): 645.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.30
• Revenue Growth: -12.96%
• EPS Growth: -1199.26%
• Country: US
• Employees: 389
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 62,413,850
• 10 Day Avg. Volume: 482,944
• 30 Day Avg. Volume: 645,116
• PEG Ratio: 0.15
• Price to Book (P/B): 3.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -59.54
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 0.48
• Enterprise Value/Gross Profit: 3.55
• Enterprise Value/Ebitda: 4.08
• 1Y Price Target: $4.50
• Price Target Upside: -9.64% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: $5.50 ▲(10.44%Upside)

Airsculpt Technologies' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and cash flow issues. Technical analysis shows bullish momentum, and recent corporate events offer some positive outlook. However, valuation concerns and mixed earnings call sentiments temper the overall score.

Positive Factors

Equity Financing

The equity financing resolves the mandatory $10m debt repayment under its existing credit commitment.

Growth Indicators

There are encouraging signs with monthly sequential case growth and an increase in lead volume.

Price Target

The 12-month price target is raised to $4.50, based on a higher multiple applied to the 2026 EBITDA forecast.

Negative Factors

Earnings Forecast

The 2025-26 EBITDA forecasts have been lowered, indicating reduced expectations for future earnings.

Liquidity

Liquidity remains tight with no revolver capacity and only $5.6m in cash.

Revenue Performance

Both 2024 revs and EBITDA missed consensus by 3% and 15%, respectively, as well as the company's guidance range.

Airsculpt Technologies Business Overview & Revenue Model

Company Description

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.

How the Company Makes Money

Airsculpt Technologies makes money primarily through the provision of its proprietary body contouring services. The company generates revenue by performing AirSculpt procedures at its network of clinics, which are strategically located to serve a broad client base. Key revenue streams include procedure fees paid by patients seeking body sculpting treatments. Additionally, the company may benefit from partnerships with healthcare providers or aesthetic clinics that offer its services as part of their portfolio. Other factors contributing to its earnings could include patient referrals, repeat business from satisfied clients, and expansion into new geographic markets.

Airsculpt Technologies Financial Statement Overview

Summary

Airsculpt Technologies is facing significant financial challenges, marked by declining revenues and persistent losses. The company has a negative net profit margin and struggles with cash flow, indicating potential risks in financial health. While the balance sheet shows some stability, the overall financial performance reflects operational inefficiencies and a need for improved cash generation.

Income Statement

Airsculpt Technologies shows declining revenue growth with a negative trend in profitability. The TTM data reveals a gross profit margin of 58.0%, but the company struggled with a net loss, leading to a negative net profit margin of -9.95%. The EBIT margin is also negative at -8.38%, indicating operational challenges. Although EBITDA margin is positive at 7.36%, it reflects a significant decline from previous periods, indicating pressure on core earnings.

Balance Sheet

The balance sheet indicates a moderate level of stability with a debt-to-equity ratio of 0.43 in the TTM period, suggesting manageable leverage. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is 38.05%, highlighting a balanced structure, yet the overall health is impacted by persistent losses.

Cash Flow

The cash flow statement shows a negative free cash flow in the TTM period, reflecting cash outflows that pressure liquidity. The operating cash flow to net income ratio is negative due to losses, and free cash flow to net income ratio is also negative, indicating strain in converting profits to cash. This could pose a risk if the trend continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	172.10M	180.35M	195.92M	168.79M	133.31M	62.77M
Gross Profit	99.93M	108.97M	121.91M	106.01M	88.78M	39.30M
EBITDA	12.67M	10.07M	19.74M	3.52M	23.05M	15.67M
Net Income	-17.13M	-8.25M	-4.48M	-14.68M	10.55M	5.75M
Balance Sheet
Total Assets	203.26M	210.00M	204.02M	200.76M	200.55M	179.61M
Cash, Cash Equivalents and Short-Term Investments	5.55M	8.23M	10.26M	9.62M	25.35M	10.38M
Total Debt	33.16M	105.05M	99.67M	107.65M	100.58M	49.77M
Total Liabilities	125.93M	130.71M	120.03M	129.99M	117.03M	55.93M
Stockholders Equity	77.33M	79.29M	83.99M	70.77M	83.53M	123.68M
Cash Flow
Free Cash Flow	-5.49M	-2.66M	14.04M	11.53M	19.52M	10.27M
Operating Cash Flow	8.85M	11.35M	23.96M	24.45M	26.63M	13.96M
Investing Cash Flow	-14.35M	-14.01M	-9.92M	-12.92M	-7.12M	-3.69M
Financing Cash Flow	77.00K	630.00K	-13.39M	-27.26M	-4.55M	-5.02M

Airsculpt Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Positive. The current price of 4.98 is below the 20-day moving average (MA) of 5.03, above the 50-day MA of 4.35, and above the 200-day MA of 4.73, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 58.87 is Neutral, neither overbought nor oversold. The STOCH value of 40.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIRS.

Airsculpt Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	75 Outperform	$1.60B	14.94	11.19%	2.48%	19.16%	31.92%
AMED	71 Outperform	$3.19B	36.19	7.85%	―	5.34%	―
USPH	70 Outperform	$1.13B	34.28	6.72%	2.42%	14.30%	76.89%
SGRY	60 Neutral	$2.82B	―	-10.43%	―	13.54%	-30732.00%
AIRS	55 Neutral	$310.82M	―	-21.30%	―	-12.96%	-1199.26%
Sector *	52 Neutral	$7.52B	0.21	-63.76%	2.30%	16.15%	0.89%
JYNT	51 Neutral	$177.51M	―	-27.25%	―	-26.14%	23.04%

Airsculpt Technologies Corporate Events

Airsculpt Technologies Completes $13.8 Million Public Offering

On June 9, 2025, AirSculpt Technologies entered into an underwriting agreement with Leerink Partners to sell 3,160,000 shares of common stock in a public offering, with an option for an additional 474,000 shares, which was fully exercised. The offering closed on June 11, 2025, raising approximately $13.8 million. The company plans to use the proceeds to prepay part of its outstanding debt and for general corporate purposes. Vesey Street Capital Partners, the company’s largest stockholder, purchased 1,000,000 shares. This move is expected to impact AirSculpt’s financial strategy by reducing debt and providing capital for business opportunities.

The most recent analyst rating on (AIRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

Airsculpt Technologies Elects Directors at Annual Meeting

On May 7, 2025, AirSculpt Technologies held its annual meeting of stockholders where two Class I directors, Yogi Jashnani and Daniel Sollof, were elected for a three-year term. Additionally, Grant Thornton was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, indicating continued stability in the company’s governance and financial oversight.